The best — and worst — biotech IPOs in the class of 2017

When we start­ed out this year, sev­er­al an­a­lysts re­marked that 2017 would ba­si­cal­ly be OK for biotech IPOs. Noth­ing like the go-go days of 2014, of course, but equal to or slight­ly bet­ter than the so-so 28 that scored in 2016.

At this stage of the game, those ear­ly fore­casts ap­pear to be right on the mon­ey — with a shot at be­ing a bit con­ser­v­a­tive. And some stand­out suc­cess­es on the IPO front are like­ly to con­tin­ue to dri­ve new of­fer­ings that are cre­at­ing bil­lions of dol­lars of share­hold­er val­ue in these fledg­ling drug com­pa­nies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.